Headlands Technologies LLC Acquires New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Headlands Technologies LLC acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,750 shares of the biotechnology company’s stock, valued at approximately $104,000.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after buying an additional 2,371,401 shares during the period. Norges Bank purchased a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $13,278,000. Kynam Capital Management LP boosted its stake in BioCryst Pharmaceuticals by 41.9% during the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock worth $33,160,000 after buying an additional 1,927,491 shares during the period. Avoro Capital Advisors LLC boosted its stake in BioCryst Pharmaceuticals by 13.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock worth $78,170,000 after buying an additional 1,500,000 shares during the period. Finally, Braidwell LP boosted its stake in BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock worth $34,254,000 after buying an additional 355,497 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ:BCRX opened at $7.92 on Monday. The firm’s 50 day moving average price is $7.66 and its 200 day moving average price is $6.27. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -7.40 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.11. The firm had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. The firm’s revenue was up 34.9% compared to the same quarter last year. During the same period last year, the business earned ($0.24) EPS. On average, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.45 EPS for the current year.

Insider Activity at BioCryst Pharmaceuticals

In related news, Director Amy E. Mckee sold 8,600 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $6.32, for a total value of $54,352.00. Following the sale, the director now owns 27,831 shares of the company’s stock, valued at $175,891.92. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BCRX has been the subject of several research analyst reports. JMP Securities increased their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 6th. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $14.17.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.